Get notified when EVGN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor identified going-concern assessment as a critical audit matter, signaling financial distress.
- Delist (new) — The company received a Nasdaq non-compliance notice for its share price below $1.00, risking delisting.
Evogene launches at-the-market offering of up to $2.93M ordinary shares at $0.60/share
Filed June 11, 2026 · ~1 min read
Key Changes
-
high
Evogene is selling up to $2,926,500 of ordinary shares in an at-the-market offering, with proceeds to the company for R&D, working capital, subsidiaries, and general purposes.
The Offering verify on EDGAR → -
medium
The offering price is $0.60 per share, based on the last reported sale price on Nasdaq on June 9, 2026; shares will be sold at market prices from time to time.
The Offering verify on EDGAR → -
high
New investors will experience immediate dilution of $0.112 per share, and the offering could increase shares outstanding by up to 40%.
Dilution verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NTSK 10-Q) is open in full — no account needed.
Partner
Trade EVGN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify